Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission.
Carpagnano GE, Portacci A, Nolasco S, Detoraki A, Vatrella A, Calabrese C, Pelaia C, Montagnolo F, Scioscia G, Valenti G, D'Amato M, Caiaffa MF, Triggiani M, Scichilone N, Crimi C. Carpagnano GE, et al. Among authors: caiaffa mf. Front Immunol. 2024 Jan 23;15:1343362. doi: 10.3389/fimmu.2024.1343362. eCollection 2024. Front Immunol. 2024. PMID: 38327518 Free PMC article.
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes.
Sposato B, Scalese M, Milanese M, Masieri S, Cavaliere C, Latorre M, Scichilone N, Ricci A, Cresti A, Santus P, Olivieri C, Perrella A, Rogliani P, Paggiaro P; Omalizumab Italian Study Group. Sposato B, et al. J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1643-1646. doi: 10.1016/j.jaip.2019.03.006. Epub 2019 Mar 19. J Allergy Clin Immunol Pract. 2019. PMID: 30898690 No abstract available.
Characteristics and treatment regimens across ERS SHARP severe asthma registries.
van Bragt JJMH, Adcock IM, Bel EHD, Braunstahl GJ, Ten Brinke A, Busby J, Canonica GW, Cao H, Chung KF, Csoma Z, Dahlén B, Davin E, Hansen S, Heffler E, Horvath I, Korn S, Kots M, Kuna P, Kwon N, Louis R, Plaza V, Porsbjerg C, Ramos-Barbon D, Richards LB, Škrgat S, Sont JK, Vijverberg SJH, Weersink EJM, Yasinska V, Wagers SS, Djukanovic R, Maitland-van der Zee AH; SHARP Clinical Research Collaboration; Members of the SHARP Clinical Research Collaboration are. van Bragt JJMH, et al. Eur Respir J. 2020 Jan 9;55(1):1901163. doi: 10.1183/13993003.01163-2019. Print 2020 Jan. Eur Respir J. 2020. PMID: 31601713 Free article.
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life.
Bagnasco D, Povero M, Pradelli L, Brussino L, Rolla G, Caminati M, Menzella F, Heffler E, Canonica GW, Paggiaro P, Senna G, Milanese M, Lombardi C, Bucca C, Manfredi A, Canevari RF, Passalacqua G; SANI Network (Severe Asthma Network Italy). Bagnasco D, et al. World Allergy Organ J. 2021 Jan 27;14(2):100509. doi: 10.1016/j.waojou.2021.100509. eCollection 2021 Feb. World Allergy Organ J. 2021. PMID: 33598095 Free PMC article.
Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression.
Pelaia C, Crimi C, Benfante A, Caiaffa MF, Calabrese C, Carpagnano GE, Ciotta D, D'Amato M, Macchia L, Nolasco S, Pelaia G, Pellegrino S, Scichilone N, Scioscia G, Spadaro G, Valenti G, Vatrella A, Crimi N. Pelaia C, et al. Among authors: caiaffa mf. J Asthma Allergy. 2021 Feb 22;14:163-173. doi: 10.2147/JAA.S297273. eCollection 2021. J Asthma Allergy. 2021. PMID: 33654413 Free PMC article.
Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study.
Nolasco S, Crimi C, Pelaia C, Benfante A, Caiaffa MF, Calabrese C, Carpagnano GE, Ciotta D, D'Amato M, Macchia L, Pelaia G, Pellegrino S, Scichilone N, Scioscia G, Spadaro G, Campisi R, Valenti G, Vatrella A, Crimi N. Nolasco S, et al. Among authors: caiaffa mf. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4371-4380.e4. doi: 10.1016/j.jaip.2021.08.004. Epub 2021 Aug 19. J Allergy Clin Immunol Pract. 2021. PMID: 34419679
Mild/Moderate Asthma Network in Italy (MANI): a long-term observational study.
Braido F, Blasi F, Canonica GW, Paggiaro P, Beghè B, Bonini M, Carpagnano GE, Del Giacco S, Lavorini F, Milanese M, Patella V, Santus P, Contoli M; MANI Network; Allegrini C, Baiardini I, Bonzano L, Caiaffa MF, Castelnuovo P, Corsico AG, Cosmi L, Costantino MT, Cottini M, Crimi N, Crivellaro MA, D'Alò S, Folletti I, Fornari D, Foschino-Barbaro MP, Franceschini L, Gargano D, Oliani KL, Maniscalco M, Melissari L, Montagni M, Montuschi P, Murgia N, Pannofino A, Papi A, Parente R, Pelaia G, Pini L, Puggioni F, Pulerà N, Resta O, Ricciardi L, Ridolo E, Savi E, Savoia F, Scala G, Senna G, Tripodi S, Vatrella A, Ventura MT, Viviano VM, Yacoub MR. Braido F, et al. Among authors: caiaffa mf. J Asthma. 2022 Sep;59(9):1908-1913. doi: 10.1080/02770903.2021.1968895. Epub 2021 Sep 1. J Asthma. 2022. PMID: 34469268 Free article.
Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis.
Di Bona D, Crimi C, D'Uggento AM, Benfante A, Caiaffa MF, Calabrese C, Campisi R, Carpagnano GE, Ciotta D, D'Amato M, Pelaia C, Pelaia G, Pellegrino S, Scichilone N, Scioscia G, Ribecco N, Spadaro G, Valenti G, Vatrella A, Crimi N, Macchia L. Di Bona D, et al. Among authors: caiaffa mf. Clin Exp Allergy. 2022 Feb;52(2):312-323. doi: 10.1111/cea.14026. Epub 2021 Oct 16. Clin Exp Allergy. 2022. PMID: 34608696 Free PMC article.
Severe asthma: One disease and multiple definitions.
Bagnasco D, Paggiaro P, Latorre M, Folli C, Testino E, Bassi A, Milanese M, Heffler E, Manfredi A, Riccio AM, De Ferrari L, Blasi F, Canevari RF, Canonica GW, Passalacqua G; SANI (Severe Asthma Network Italy); Severe Asthma Network Italy. Bagnasco D, et al. World Allergy Organ J. 2021 Nov 19;14(11):100606. doi: 10.1016/j.waojou.2021.100606. eCollection 2021 Nov. World Allergy Organ J. 2021. PMID: 34871335 Free PMC article.
70 results